---
title: "Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291403557.md"
description: "Guggenheim analyst Vamil Divan maintained a Buy rating on Unicycive Therapeutics (UNCY) with a $37 price target, despite shares closing at $4.69. B. Riley Securities also issued a Buy rating with a $22 target. UNCY holds a Strong Buy consensus among analysts, with an average price target of $40.33, implying significant upside potential."
datetime: "2026-07-01T10:55:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291403557.md)
  - [en](https://longbridge.com/en/news/291403557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291403557.md)
generator: "portal-rs"
---

# Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)

In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Unicycive Therapeutics, with a price target of $37.00. The company’s shares closed yesterday at $4.69.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Divan covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Merck & Company, and Pfizer. According to TipRanks, Divan has an average return of 14.0% and a 58.54% success rate on recommended stocks. 

Unicycive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.33, representing a 759.91% upside. In a report released yesterday, B. Riley Securities also maintained a Buy rating on the stock with a $22.00 price target.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)
- [RILY.US](https://longbridge.com/en/quote/RILY.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders](https://longbridge.com/en/news/296708926.md)
- [14:00 ET$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC](https://longbridge.com/en/news/296707798.md)
- [Unicycive Therapeutics Gets Complete Response Letter From FDA On Resubmitted Oxylanthanum Carbonate NDA](https://longbridge.com/en/news/291272311.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**